IB Traders’ Insight

View The Latest Videos View Videos

1 2 3 4 5 2 1739


Macro

The Opportunistic Trader - Overnight Recap 11/20


Where is our Santa Rally?

 

Following yesterday’s tech heavy sell off Asian and European markets are down over 1%.

 

Target has issues disappointing margins which is pressuring retail stocks to start the day.

Global stock markets were mostly lower overnight, following the solid losses posted in the U.S. stock indexes on Monday. Technology stocks are taking the brunt of the selling pressure recently. It still appears the U.S. stock indexes put in at least near-term tops last month, if not major market tops. U.S. stock indexes are pointed toward weaker openings when the New York day session begins.

It could be a quieter trading week as the U.S. Thanksgiving holiday falls on Thursday. U.S. markets close early Wednesday, with Friday the “Black Friday” sale affair that finds many traders and investors out for the day, shopping for Christmas gift deals.

The key outside markets today find the U.S. dollar index trading slightly higher and not far below this month’s 1.5-year high. Meantime, Nymex crude oil futures prices are slightly higher on a corrective bounce after hitting an 11-month low last week.

U.S. economic data due for release Tuesday includes the weekly Johnson Redbook and Goldman Sachs retail sales reports, and new residential construction.

 

U.S. STOCK INDEXES

December S&P 500 e-mini futures: Prices are weaker in early U.S. trading. Bears have regained downside momentum. The shorter-term moving averages (4-, 9- and 18-day) are neutral early today. The 4-day moving average is below the 9-day and 18-day. The 9-day is above the 18-day moving average. Short-term oscillators (RSI, slow stochastics) are bearish early today. Today, shorter-term technical resistance comes in at 2,700.00 and then at 2,725.00. Buy stops likely reside just above those levels. Downside support for active traders today is located at last week’s low of 2,671.25 and then at 2,650.00. Sell stops are likely located just below those levels.

December Nasdaq index December futures: Prices are lower and hit a seven-month low in early U.S. trading. Shorter-term moving averages (4- 9-and 18-day) are bearish early today. The 4-day moving average is below the 9-day and 18-day. The 9-day average is below the 18-day. Short-term oscillators (RSI, slow stochastics) are bearish early today. Shorter-term technical resistance is seen at the overnight high of 6,670.00 and then at 6,700.00. Buy stops likely reside just above those levels. On the downside, short-term support is seen at the overnight low of 6,574.25 and then at 6,500.00. Sell stops are likely located just below those levels.

 

U.S. TREASURY BONDS AND NOTES

December U.S. T-Bonds: Prices are higher and hit a seven-week high in early U.S. trading today, on some safe-haven demand amid a wobbly U.S. stock market, and on short covering. Shorter-term moving averages (4- 9- 18-day) are bullish early today. The 4-day moving average is above the 9-day and 18-day. The 9-day is above the 18-day moving average. Oscillators (RSI, slow stochastics) are bullish early today. Shorter-term technical resistance is seen at the overnight high of 140 4/32 and then at 140 16/32. Buy stops likely reside just above those levels. Shorter-term support lies at the overnight low of 139 19/32 and then at 139 10/32. Sell stops likely reside just below those levels.

December U.S. T-Notes: Prices are slightly up and hit a seven-week high in early U.S. trading. Shorter-term moving averages (4- 9- 18-day) are bullish early today. The 4-day moving average is above the 9-day and 18-day. The 9-day is above the 18-day moving average. Oscillators (RSI, slow stochastics) are neutral to bullish early today. Shorter-term resistance lies at the overnight high of 119.14.0 and then at 119.20.0. Buy stops likely reside just above those levels. Shorter-term technical support lies at the overnight low of 119.06.0 and then at 119.00.0. Sell stops likely reside just below those levels.

 

U.S. DOLLAR INDEX

The December U.S. dollar index is firmer in early U.S. trading. Bulls have the firm overall near-term technical advantage. The shorter-term moving averages for the dollar index are neutral early today, as the 4-day is below the 9-day and 18-day. The 9-day is above the 18-day moving average. Short-term oscillators for the dollar index are neutral early today. The dollar index finds shorter-term technical resistance at the Monday’s high of 96.435 and then at last Friday’s high of 96.920. Shorter-term support is seen at the overnight low of 95.930 and then at the November low of 95.485.

 

NYMEX CRUDE OIL

January Nymex crude oil prices are near steady in early U.S. trading. Bears are still in solid near-term technical control. There are still no early clues that a market bottom is close at hand. The shorter-term moving averages are bearish early today as the 4-day is below the 9-day and 18-day. The 9-day is below the 18-day moving average. Short-term oscillators (RSI and slow stochastics) are neutral early today. Look for buy stops to reside just above technical resistance at last Friday’s high of $58.16 and then at $59.00. Look for sell stops just below technical support at the overnight low of $56.51 and then at $56.00.

 

GRAINS

Grain futures prices were steady to narrowly mixed overnight. There are mixed ideas in the grain markets regarding the U.S. and China reaching a trade deal any time soon. Look for the markets to continue to gyrate on fresh news regarding the matter. The grain market bears still have the overall near-term technical advantage.

--

At The Opportunistic Trader we have created an interactive community to help traders of all levels across all asset classes become more informed and more consistent traders. In our live stream, as a community, we congregate daily to talk about the markets, strategize, assess the landscape, react to breaking news and share the best ideas from our experienced traders.  Our traders have managed billions of dollars in client assets with exceptional track records. Our team features traders from the popular book series “Market Wizards” to legends from the trading pits and NYSE floor.  We conduct the same daily market analysis today in the chat room as we have our entire career. We take our jobs very seriously and aim to give our customers profitable trade ideas, market observations and access to a community of like-minded traders.

The principals, officers, employees, agents and affiliates (including a\ny “Experts”) of The Opportunistic Trader are active investors and engage in the trading of securities for their own personal accounts. Such parties may, but are not required to, purchase or sell any securities, or engage in any investment strategy, contained in any data, content or information on the Web Site, or in the other TOT products or services.  The terms “expert” or “expertise” as used in the Web Site should not be construed to mean, with respect to any individual (TOT employee, affiliate or otherwise) any qualification other than those which have been expressly specified therein.  Such terms should not be construed to imply any registration or other qualification.  We are publishers and educators only. The information contained on this website is for educational and informational purposes only It does not constitute investment advice of any kind. The risk of trading in the securities, commodities and/or futures markets can be substantial. You must review and agree to our Terms and Conditions before using this site. This website is neither a solicitation nor an offer to buy or sell securities, commodities, futures or options. No representation is being made that any person or account will or is likely to achieve profits or losses similar to those discussed on this website. The past performance of any trading system or methodology is not necessarily indicative of future results. These results are based on simulated or hypothetical performance results that have certain inherent limitations. Unlike the results shown in an actual performance record, these results do not represent actual trading. Also, because these trades have not actually been executed, these results may have under-or over-compensated for the impact, if any, of certain market factors, such as lack of liquidity. Simulated or hypothetical trading programs in general are also subject to the fact that they are designed with the benefit of hindsight. No representation is being made that any account will or is likely to achieve profits or losses similar to these being shown. The Web Site may contain links to other external websites or applications (“Third Party Websites”). However, we are under no obligation to verify the accuracy of the contents on such Third Party Websites, and we do not endorse, warrant, promote or recommend any services or products that may be offered by or accessed through such Third Party Websites or the operators of them. Your use of links to Third Party Websites is at your own risk.

Information posted on IBKR Traders’ Insight that is provided by third-parties and not by Interactive Brokers does NOT constitute a recommendation by Interactive Brokers that you should contract for the services of that third party. Third-party participants who contribute to IBKR Traders’ Insight are independent of Interactive Brokers and Interactive Brokers does not make any representations or warranties concerning the services offered, their past or future performance, or the accuracy of the information provided by the third party. Past performance is no guarantee of future results.

This material is from The Opportunistic Trader and is being posted with The Opportunistic Trader’s permission. The views expressed in this material are solely those of the author and/or The Opportunistic Trader and IBKR is not endorsing or recommending any investment or trading discussed in the material. This material is not and should not be construed as an offer to sell or the solicitation of an offer to buy any security. To the extent that this material discusses general market activity, industry or sector trends or other broad based economic or political conditions, it should not be construed as research or investment advice. To the extent that it includes references to specific securities, commodities, currencies, or other instruments, those references do not constitute a recommendation to buy, sell or hold such security. This material does not and is not intended to take into account the particular financial conditions, investment objectives or requirements of individual customers. Before acting on this material, you should consider whether it is suitable for your particular circumstances and, as necessary, seek professional advice.


21605




Technical Analysis

Gramza - Technical Analysis (Gold, Dollar, Oil and more) Heading into Tuesday's Open


Dan Gramza takes a look at some key charts heading into today's open, including gold, oil and the dollar.

This Daily Market Studies are presented by an unaffiliated third party and Interactive Brokers LLC does not create the content of these presentations. You should review the contents of each presentation and make your own judgment as to whether the content is appropriate for you. Interactive Brokers LLC does not provide recommendations or advice. This presentation is not an advertisement or solicitation for new customers. It is intended only as an educational presentation.

Information posted on IBKR Traders’ Insight that is provided by third-parties and not by Interactive Brokers does NOT constitute a recommendation by Interactive Brokers that you should contract for the services of that third party. Third-party participants who contribute to IBKR Traders’ Insight are independent of Interactive Brokers and Interactive Brokers does not make any representations or warranties concerning the services offered, their past or future performance, or the accuracy of the information provided by the third party. Past performance is no guarantee of future results.

This material is from Dan Gramza and is being posted with Dan Gramza’s permission. The views expressed in this material are solely those of the author and/or Dan Gramza and IBKR is not endorsing or recommending any investment or trading discussed in the material. This material is for information only and is not and should not be construed as an offer to sell or the solicitation of an offer to buy any security. To the extent that this material discusses general market activity, industry or sector trends or other broad-based economic or political conditions, it should not be construed as research or investment advice. To the extent that it includes references to specific securities, commodities, currencies, or other instruments, those references do not constitute a recommendation by IBKR to buy, sell or hold such security. This material does not and is not intended to take into account the particular financial conditions, investment objectives or requirements of individual customers. Before acting on this material, you should consider whether it is suitable for your particular circumstances and, as necessary, seek professional advice.

 


21602




Macro

Briefing.com - Knock-Knock


Anyone having a tough time remembering how the stock market behaved on Monday needn't fear.  It should come back to them at today's open, which is setting up to be a negative one on account of follow-through selling in the FAANG stocks, other growth/momentum stocks, weakness in the retail space, and relatively weak housing market data.

Currently, the S&P futures are down 41 points and are trading 1.4% below fair value.  The Nasdaq 100 futures are down 154 points and are trading 2.0% below fair value.  The Dow Jones Industrial Average futures are down 375 points and are trading 1.4% below fair value.

There was a steady degradation in the futures market that started around 2:00 a.m. ET, which coincided with weak showings from Asian markets, although selling interest has picked up more recently as earnings reports from several retailers have had a disappointing hue.

Target (TGT), Kohl's (KSS), Lowe's (LOW), and L Brands (LB) are all down between 8.0% and 12.0% for a range of reasons that include concerns about gross margin pressures, elevated inventory levels, weaker than expected comparable store sales, and difficult comparisons in 2019.

Those reasons don't apply in all cases, yet one reason is enough in this market, which is caught up in growth concerns that have led to a de-risking effort.

The FAANG stocks and information technology sector were at the epicenter of Monday's de-risking move, falling victim to liquidation efforts that were liked to an unwinding of crowded trades that flowed from worries about a cyclical slowdown, valuations, and increased regulatory scrutiny.

Facebook (FB), Apple (AAPL), Amazon.com (AMZN), Netflix (NFLX), and Alphabet (GOOG) are all in a bear market and are all indicated at least 2.0% lower in pre-market trading.

Just like Monday, the weight of those losses is expected to pressure the broader market, not just from a market-cap standpoint but also from a sentiment standpoint.

These stocks are widely owned and they have "always worked," which means they have left a lot of owners taken aback by their technical breakdown and the lack of any buy-the-dip assertiveness that has sustained them time and again in this bull market.

In a certain respect, this market is waiting for them to show up again to instill some confidence in the idea that the broader-market sell-off has run its course.  

The weakness in those former leadership names (well, they are still leadership stocks, only now they are leading to the downside) is one knock on this market. 

Another knock is that the seasonal trading cheer typically seen this time of year has tilted to the moody side so far.  Granted there are still some decent winners this month (the real estate sector is up 4.4%), yet the weight of losses in the information technology (-5.5%), communication services (-4.5%), and consumer discretionary (-2.0%) sectors has the S&P 500 down 0.8% in November.

That's not a knock-knock joke, but it begs the question everyone is waiting to see answered: who's there?

Who will be there to save the seasonal day?  Will it be the FAANG stocks?  Will it be the bloodied semiconductor stocks?  Will it be President Trump and President Xi at the G20 Summit?  Will it be the Fed?

Answers all unknown at this point, which is why the price action remains key.

Shifting gears, housing starts increased 1.5% month-over-month in October to a seasonally adjusted annual rate of 1.228 million units (Briefing.com consensus 1.230 million).  Building permits slipped 0.6% to a seasonally adjusted annual rate of 1.263 million (Briefing.com consensus 1.260 million) from an upwardly revised 1.270 million (from 1.241 million) in September.

The key takeaway from the report, however, is that there wasn't any strength in single-unit permits or starts, which were down 0.6% and 1.8%, respectively, month-over-month and down 0.6% and 2.6%, respectively, year-over-year.

Single-unit starts were down across all regions, with the exception of the Northeast (+14.8%), which also happens to be the smallest region for housing starts.

The Housing Starts and Building Permits report might have passed the consensus estimate headline test, yet it isn't a report that should be seen as assuaging concerns about the softness in housing market activity.  If anything, it plays right into those concerns with the year-over-year declines for total permits (-6.0%) and total starts (-2.9%).

--Patrick J. O'Hare, Briefing.com

--

Briefing In Play offers live market-moving analysis, earnings and news coverage, broker ratings changes, as well as comprehensive economic coverage and commentary. Briefing in Play Plus includes everything in Briefing In Play, and features investment idea generation and in-depth analysis. Briefing Trader includes everything in Briefing In Play Plus, and features live trading ideas with specific entry/exit points as well as access to the new streaming audio feature, Trader Audio.

Information posted on IBKR Traders’ Insight that is provided by third-parties and not by Interactive Brokers does NOT constitute a recommendation by Interactive Brokers that you should contract for the services of that third party. Third-party participants who contribute to IBKR Traders’ Insight are independent of Interactive Brokers and Interactive Brokers does not make any representations or warranties concerning the services offered, their past or future performance, or the accuracy of the information provided by the third party. Past performance is no guarantee of future results.

This material is from Briefing.com and is being posted with Briefing.com's permission. The views expressed in this material are solely those of the author and/or Briefing.com and IBKR is not endorsing or recommending any investment or trading discussed in the material. This material is for information only and is not and should not be construed as an offer to sell or the solicitation of an offer to buy any security. To the extent that this material discusses general market activity, industry or sector trends or other broad-based economic or political conditions, it should not be construed as research or investment advice. To the extent that it includes references to specific securities, commodities, currencies, or other instruments, those references do not constitute a recommendation by IBKR to buy, sell or hold such security. This material does not and is not intended to take into account the particular financial conditions, investment objectives or requirements of individual customers. Before acting on this material, you should consider whether it is suitable for your particular circumstances and, as necessary, seek professional advice.


21600




Stocks

Benzinga - The Daily Biotech Pulse: Denali's Positive Results, Novartis' Substance Abuse Therapy Launch, Medtronic Earnings - Shanthi Rexaline


Here's a roundup of top developments in the biotech space over the last 24 hours.

Scaling The Peak

(Biotech stocks hitting 52-week highs on Nov. 19)

  • Merck & Co., Inc. MRK

 

Down In The Dumps

(Biotech stocks hitting 52-week lows on Nov. 19)

  • Adamas Pharmaceuticals Inc ADMS
  • Aduro BioTech Inc ADRO
  • Cancer Genetics Inc CGIX
  • Cue Biopharma Inc CUE
  • Enzo Biochem, Inc. ENZ
  • Diffusion Pharmaceuticals Inc DFFN 3.3%
  • Foamix Pharmaceuticals Ltd FOMX (announced resignation of Darrell Rigel from the board and the appointment of Anthony Bruno to the board)
  • Innovate Biopharmaceuticals Inc INNT
  • Keryx Biopharmaceuticals KERX
  • Neos Therapeutics Inc NEOS
  • Neovasc Inc NVCN
  • Neuronetics Inc STIM
  • Sonoma Pharmaceuticals Inc SNOA
  • Spark Therapeutics Inc ONCE
  • Stellar Biotechnologies Inc SBOT 0.01%
  • Stemline Therapeutics Inc STML
  • SUMMIT THERAPEU/S ADR SMMT
  • Teligent IncTLGT
  • VIVUS, Inc. VVUS

 

Stocks In Focus

J&J's Janssen Unit Initiates Mid-stage Trial For Skin Disease Drug Developing Using Morphosys' Technology

MORPHOSYS AG/S ADR MOR announced Johnson & Johnson JNJ unit Janssen, which has licensed its proprietary HuCAL antibody technology for developing guselkumab that is being evaluated for treating patients with moderate to severe hidradenitis suppurativa, a kind of chronic skin disease, has initiated a Phase 2 trial.

The trial is expected to enroll about 180 adult patients.

 

Denali Reports Positive Phase 1 Results For Drug Studied For Neurologic and Systemic Inflammatory Diseases

Denali Therapeutics Inc DNLI announced positive Phase 1 healthy volunteer study of its lead molecule DNL747 - a brain penetrant small molecule inhibitor of receptor-interacting serine/threonine-protein kinase 1. In a study of 56 healthy subjects who received either single or multiple ascending doses or placebo, the pipeline asset achieved its safety, pharmacokinetic, and pharmacodynamic objectives.

"DNL747 was generally well tolerated with no serious adverse events at doses that achieved high levels of brain exposure and robust target engagement as measured by a blood-based biomarker of RIPK1 activity," the company said.

Denali also said along with its partner Sanofi SA SNY, it will evaluate DNL747 in clinical studies for Alzheimer's disease, amyotrophic lateral sclerosis, and multiple sclerosis.

 

Novartis' Sandoz Unit Commercially Launches Therapy For Substance Abuse

Novartis AG NVS unit Sandoz and Pear Therapeutics announced the commercial launch of reSET, a FDA-approved prescription digital therapeutic, for patients with substance use disorder.

 

On The Radar

Earnings

  • Medtronic PLC MDT Q2 Adj. EPS $1.22 Beats $1.15 Estimate, Sales $7.5B Beat $7.35B Estimate; Raises Organic Sales Growth Guidance From 4.5%-5.0% To 5.0%-5.5%

--

© 2018 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Benzinga is a fast-growing financial media outlet that empowers investors with market-moving content. The site also manages Benzinga Pro, a streaming platform with real-time headlines, data and actionable alerts. Sign up for a free trial and profit with faster news now.

Information posted on IBKR Traders’ Insight that is provided by third-parties and not by Interactive Brokers does NOT constitute a recommendation by Interactive Brokers that you should contract for the services of that third party. Third-party participants who contribute to IBKR Traders’ Insight are independent of Interactive Brokers and Interactive Brokers does not make any representations or warranties concerning the services offered, their past or future performance, or the accuracy of the information provided by the third party. Past performance is no guarantee of future results.

This material is from Benzinga and is being posted with Benzinga's permission. The views expressed in this material are solely those of the author and/or Benzinga and IBKR is not endorsing or recommending any investment or trading discussed in the material. This material is not and should not be construed as an offer to sell or the solicitation of an offer to buy any security. To the extent that this material discusses general market activity, industry or sector trends or other broad based economic or political conditions, it should not be construed as research or investment advice. To the extent that it includes references to specific securities, commodities, currencies, or other instruments, those references do not constitute a recommendation to buy, sell or hold such security. This material does not and is not intended to take into account the particular financial conditions, investment objectives or requirements of individual customers. Before acting on this material, you should consider whether it is suitable for your particular circumstances and, as necessary, seek professional advice.


21599




Stocks

The Hammerstone Report - Early Look


U.S. stock futures are down globally after a rout in U.S. stocks yesterday, led by sharp declines in the technology space, which carried over to weakness in Europe and Asia overnight on this holiday shortened week. In Asian markets, The Nikkei Index fell -238 points to 21,583, the Shanghai Index dropped -57 points (2.13%) to settle at 2,645 and the Hang Seng Index plunged -531 points or over 2% to finish at 25,840. In Europe, the German DAX is down around -90 points at 11,150, while the FTSE 100 is down over -30 points moving back under the 7,000 level. Asian market declines were led by technology shares, following the sharp declines in the U.S. the day prior. In the U.S. today, a very busy morning of earnings in the retail space, with shares of Target (TGT) falling after quarterly results missed estimates. Oil prices are little changed while the dollar looks to rebound off losses yesterday following a weak housing data report. The continued plunge in Bitcoin continues, as prices fall another 8% to around $4,400, nearly 80% off its all-time highs. U.S. stocks tumbled on Monday sending all major indexes into the red for the month, with technology the biggest drag as the Nasdaq Composite fell over 3% on the day in broad based selling of software, semiconductors and Internet stocks. The iShares North American Tech-Software ETF (IGV) fell the most on Monday, down -5.4%, with weakness in shares of CRM, ADBE, ORCL, SPLK, OKTA, ZS among them. Trade concerns amid heated trade talk from Vice President Pence against China over the weekend at a summit also weighed on market sentiment. Meanwhile, the Dow Industrials fell over -500 points at its lows while the S&P 500 index closed back below the 2,700 level.

Market Closing Prices Yesterday

  • The S&P 500 Index dropped -45.54 points, or 1.66%, to 2,670.73
  • The Dow Jones Industrial Average fell -395.78 points, or 1.56%, to 25,017.44
  • The Nasdaq Composite plunged -219.40 points, or 3.03%, to 7,028.48
  • The Russell 2000 Index declined -30.99 points, or 2.03% to 1,496.54

 

Events Calendar for Today

  • 7:45 AM EST       ICSC Weekly Retail Sales
  • 8:30 AM EST       Housing Starts MoM for Oct…est. 1.228M
  • 8:30 AM EST       Building Permits MoM for Oct…est. 1.26M
  • 8:55 AM EST       Johnson/Redbook Weekly Sales
  • 4:30 PM EST        API Weekly Inventory Data

 

Earnings Calendar:

  • Earnings Before the Open: ADI, BBY, BKS, CPB, DY, HRL, JEC, KSS, LOW, MMS, NJR, ROST, SSI, TGT, TJX
  • Earnings After the Close: ADSK, BJ, CAL, ESL, FL, GPS, KEYS, QADB, RAVN

 

 

Macro

Up/Down

Last

WTI Crude

0.12

57.32

Brent

-0.11

66.68

Gold

-1.20

1,224.10

EUR/USD

-0.002

1.1434

JPY/USD

-0.09

112.46

10-Year Note

-0.011

3.052%

 

 

Sector News Breakdown

Consumer

  • Target (TGT) shares fall -9%; Q3 EPS $1.09/$17.8B vs. est. $1.12/$17.8B; Q3 comp sales growth rose 5.1% vs. est. 5.2%; comparable digital channel sales grew 49% and contributed 1.9 percentage points of comparable sales growth
  • Lowe's (LOW) Q3 EPS $1.04/$17.4B vs. est. 98c/$17.36B; reports Q3 comp sales up 1.5% vs. est. 2.9% and U.S. comp sales up 2%; lowers year EPS view to $4.08-$4.24 vs. prior $4.50-$4.60 and sees year comp sales about 2.5%
  • Hormel Foods (HRL) Q4 EPS 51c/$2.52B vs. est. 49c/$2.57B
  • L Brands (LB) Q3 EPS 16c/$2.77B vs. est. 15c/ $2.78B; increased its full year 2018 adjusted earnings per share guidance to $2.60-$2.80 from $2.45-$2.70 previously; to cut annual dividend to $1.20 from $2.40
  • Jack in the Box (JACK) Q4 EPS 77c/$177.5M vs. est. 85c/$175.02M; authorizes additional $60M stock buyback program; 4Q Jack system comparable sales +0.5%, vs. estimate +1% and 4Q Jack company comparable sales +0.8%, estimate +1.1%
  • Urban Outfitters (URBN) Q3 EPS 70c/$973.5M vs. est. 62c/$968.4M; as of October 31, 2018, total inventory increased by $1.7 million, or 0.4%, on a year-over-year basis; Q3 comp sales 8% vs. est. 6.3%; Comparable retail segment sales growth by brand: Free People +12%, Urban Outfitters +7%, Anthropologie Group +8%.
  • Beacon Roofing (BECN) Q4 adjusted EPS $1.07/$1.94B vs. est. $1.36/$2.01B
  • Limbach (LMB) Q3 EPS loss (46c) vs (12c) last year and reports Q3 revenue $135.1M vs. est. $140.77M; backs FY18 revenue view $530M-$550M and backs FY18 adjusted EBITDA view $8M-$10M

 

Energy, Materials and Industrials

  • A bill that would help PG&E Corp. (PCG) absorb liabilities from this year’s fatal wildfires in California is being drafted at the request of a state assemblyman who helped shepherd earlier legislation on the issue. Kellie Smith, an adviser to assemblyman Chris Holden, said she is writing the bill that could be introduced as early as Dec. 3
  • Boeing (BA) will answer questions about the 737 Max today on a conference call with airlines that fly the model involved in the Indonesia crash, Bloomberg reported
  • Jacobs Engineering (JEC) Q4 EPS $1.31/$4.14B vs. est. $1.24/$4.28B

 

Financials

  • Intuit (INTU) Q1 EPS 29c/$1.02B vs. est. 11c/$969.18M; sees Q2 EPS 85c-88c on revs $1.47B-$1.49B vs. est. 77c/$1.45B; backs FY19 adjusted EPS view $6.40-$6.50 and backs FY19 revenue view $6.53B-$6.63B (est. $6.48/$6.61B)
  • LPL Financial (LPLA), a wholly owned subsidiary of LPL Financial Holdings released its monthly activity report for October. Total brokerage and advisory assets served at the end of October were approximately $649 billion, a 4.7% decrease compared to the end of September 2018. Total net new assets for October were an inflow of $2.2B.

 

Healthcare

  • Agilent (A) Q4 EPS 81c/$1.29B vs. est. 74c/$1.25B; sees Q1 adjusted EPS 71c-73c on revs $1.265B-$1.28B vs. est. 72c/$1.27B; sees FY19 adjusted EPS $3.00-$3.05 on revs $5.13B-$5.17B vs. est. $2.96/$5.18B; authorizes new $1.75B share repurchase program
  • Boston Scientific Corp. (BSX) agreed to buy rival BTG Corp. for 3.3 billion pounds ($4.2 billion) to expand its offering of medical devices to treat cancer and other disorders
  • Medtronic (MDT) Q2 EPS $1.22/$7.48B vs. est. $1.15/$7.35B; boosts FY19 organic revenue growth guidance to up 5%-5.5% from prior view 4.5%-5%

 

Technology, Media & Telecom

  • Nuance (NUAN) Q4 EPS 38c/$536.2M vs. est. 32c/$525M; Q4 organic revenue grew 12%, operating margin of 30.5%, compared to 20.7% in the prior year period; announced its intention to spin off its Automotive business segment into a new, independent, publicly traded company
  • Pure Storage (PSTG) Q3 EPS 13c/$372.8M vs. est. 9c/$367.4M; Q3 gross margin: 66.8% GAAP; 68.1% non-GAAP, representing an all-time high; announced Pure Storage Cloud Data Services, a suite of new cloud offerings that run on Amazon Web Services; sees Q4 revenue $438M-$446M vs. est. $440.65M; sees Q4 Non-GAAP gross margin 64.5%-67.5% and non-GAAP operating margin 8%-12%; raises FY19 revenue view to $1.376B-$1.384B from $1.35B-$1.38B
  • Brooks Automation (BRKS) Q4 EPS 40c/$159.6M vs. est. 38c/$205.6M; sees Q1 revs $170M-$180M and EPS 10c-14c

--

The content of this post was created by the Hammerstone Group. The Hammerstone Institutional Forum, a chat-based platform for traders, provides subscribers with up-to-the-minute breaking news headlines and instant analysis that drive the market. For more information please visit www.thehammerstone.com. For more information on the stocks mentioned in the Hammerstone Recap, please contact Brian Ducey at brian@thehammerstone.com.

Information posted on IBKR Traders’ Insight that is provided by third-parties and not by Interactive Brokers does NOT constitute a recommendation by Interactive Brokers that you should contract for the services of that third party. Third-party participants who contribute to IBKR Traders’ Insight are independent of Interactive Brokers and Interactive Brokers does not make any representations or warranties concerning the services offered, their past or future performance, or the accuracy of the information provided by the third party. Past performance is no guarantee of future results.

This material is from the Hammerstone Group and is being posted with the Hammerstone Group's permission. The views expressed in this material are solely those of the author and/or the Hammerstone Group and IBKR is not endorsing or recommending any investment or trading discussed in the material. This material is for information only and is not and should not be construed as an offer to sell or the solicitation of an offer to buy any security. To the extent that this material discusses general market activity, industry or sector trends or other broad-based economic or political conditions, it should not be construed as research or investment advice. To the extent that it includes references to specific securities, commodities, currencies, or other instruments, those references do not constitute a recommendation by IBKR to buy, sell or hold such security. This material does not and is not intended to take into account the particular financial conditions, investment objectives or requirements of individual customers. Before acting on this material, you should consider whether it is suitable for your particular circumstances and, as necessary, seek professional advice.


21598




1 2 3 4 5 2 1739

Disclosures

We appreciate your feedback. If you have any questions or comments about IB Traders' Insight please contact ibti@ibkr.com.

The material (including articles and commentary) provided on IB Traders' Insight is offered for informational purposes only. The posted material is NOT a recommendation by Interactive Brokers (IB) that you or your clients should contract for the services of or invest with any of the independent advisors or hedge funds or others who may post on IB Traders' Insight or invest with any advisors or hedge funds. The advisors, hedge funds and other analysts who may post on IB Traders' Insight are independent of IB and IB does not make any representations or warranties concerning the past or future performance of these advisors, hedge funds and others or the accuracy of the information they provide. Interactive Brokers does not conduct a "suitability review" to make sure the trading of any advisor or hedge fund or other party is suitable for you.

Securities or other financial instruments mentioned in the material posted are not suitable for all investors. The material posted does not take into account your particular investment objectives, financial situations or needs and is not intended as a recommendation to you of any particular securities, financial instruments or strategies. Before making any investment or trade, you should consider whether it is suitable for your particular circumstances and, as necessary, seek professional advice. Past performance is no guarantee of future results.

Any information provided by third parties has been obtained from sources believed to be reliable and accurate; however, IB does not warrant its accuracy and assumes no responsibility for any errors or omissions.

Any information posted by employees of IB or an affiliated company is based upon information that is believed to be reliable. However, neither IB nor its affiliates warrant its completeness, accuracy or adequacy. IB does not make any representations or warranties concerning the past or future performance of any financial instrument. By posting material on IB Traders' Insight, IB is not representing that any particular financial instrument or trading strategy is appropriate for you.